Cardiovascular Health
Large real‑world study finds tirzepatide and semaglutide cut cardiovascular risk in type 2 diabetes
An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya
Researchers led by Mass General Brigham and the Technical University of Munich report that tirzepatide and semaglutide are associated with significant reductions in heart attacks, strokes and death among adults with type 2 diabetes at elevated cardiovascular risk. Drawing on nearly one million insurance records, the Nature Medicine analysis finds strong and early heart protection from both GLP‑1–based drugs, with only modest differences between them.
A comprehensive meta-analysis shows that well-planned vegetarian and vegan diets can support healthy growth in children and offer cardiovascular benefits. However, the review highlights risks of nutrient deficiencies like vitamin B12 and calcium without proper supplementation. Researchers urge parents to consult professionals for balanced plant-based nutrition.